Viatris is bucking the trend of major pharma players exiting the consumer health market by partially reversing its decision to divest its OTC business.
The Canonsburg, PA-based firm described OTC as “non core” in November 2022 as it put the business up for sale...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?